![]() |
NEW YORK, Sept. 22, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins.
NYSE Content Advisory: Pre-Market update + Mike Waltz, U.S. Ambassador to UN, rings Opening Bell jwplayer(‘myplayer1’).setup(file: ‘https://mma.prnasia.com/media2/2778565/NYSE_Market_Update_Sept_22.mp4’, image: ‘https://mma.prnasia.com/media2/2778565/NYSE_Market_Update_Sept_22.mp4?p=thumbnail’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’);
Ashley Mastronardi delivers the pre-market update on September 22nd
- Equities are fractionally lower on Monday following a winning week for the market as both the S&P 500 and DOW closed at a record. Small caps also rose, with the Russell 2000 climbing 2.2%, marking its seventh straight week of gains.
- According to the latest data, markets are now pricing in two more rate cuts by the end of the year. Later this week, investors will view the Fed’s preferred inflation gauge, the PCE.
- World leaders will descend up NYC and the NYSE amid the 80th U.N. General Assembly this week. Mike Waltz, newly appointed U.S. Ambassador to the United Nations, will ring today’s Opening Bell.
Opening Bell
Ambassador Mike Waltz, Representative of the United States to the United Nations, rings the Opening Bell
Closing Bell
José Raúl Mulino Quintero, President of the Republic of Panama, rings the Closing Bell
Click here to download the NYSE TV App
Video – https://mma.prnasia.com/media2/2778565/NYSE_Market_Update_Sept_22.mp4
ข่าวที่เกี่ยวข้อง
- METiS TechBio, the World’s First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, “The SpaceX of Pharmaceuticals” Ushers in a New Era of Biopharmaceuticals
- Join the 2026 SDG Asia Expo to “Shape Our Future” for Sustainability in Asia
- Hi & Fi Asia-China 2026 Enters One-Month Countdown, Connecting Asia’s Food & Health Industry in Shanghai
- MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
